{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Poorly+Differentiated+Neuroendocrine+Carcinomas", "query": { "condition": "Poorly Differentiated Neuroendocrine Carcinomas" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Poorly+Differentiated+Neuroendocrine+Carcinomas&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T04:51:54.391Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04079712", "title": "Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Large Cell Neuroendocrine Carcinoma", "Metastatic Neuroendocrine Carcinoma", "Metastatic Neuroendocrine Neoplasm", "Metastatic Small Cell Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2020-08-06", "completion_date": "2026-08-19", "has_results": true, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-05-22T04:51:54.391Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04079712" }, { "nct_id": "NCT00499733", "title": "Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Cryoablation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 19, "start_date": "2007-06", "completion_date": "2013-01-09", "has_results": false, "last_update_posted_date": "2019-01-18", "last_synced_at": "2026-05-22T04:51:54.391Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499733" }, { "nct_id": "NCT02595424", "title": "Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Neuroendocrine Carcinoma", "Intestinal Neuroendocrine Carcinoma", "Pancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2015-11-06", "completion_date": "2029-01-01", "has_results": true, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-05-22T04:51:54.391Z", "location_count": 673, "location_summary": "Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more", "locations": [ { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02595424" }, { "nct_id": "NCT03896958", "title": "The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer, All Types", "Cancer of Liver", "Cancer of Stomach", "Cancer of Head and Neck", "Cancer of Rectum", "Cancer of Kidney", "Cancer of Esophagus", "Cancer of Colon", "Cancer Skin", "Cancer of Cervix", "Cancer, Metastatic", "Cancer of Larynx", "Cancer of Neck", "Cancer of Lung", "Cancer of Brain and Nervous System", "Cancer of Vulva, Disseminated", "Cancer of Pancreas", "Sarcoma", "GIST", "Small-cell Lung Cancer", "Adenocarcinoma Lung", "Cancer of Prostate", "Cancer, Advanced", "Adrenal Cancer", "Testicular Cancer", "Uterine Cancer", "Bronchoalveolar Cell Lung Cancer", "Cancer Unknown Primary", "Glioblastoma Multiforme", "Oligodendroglioma", "Breast Cancer", "Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Cholangiocarcinoma", "Squamous Cell Carcinoma", "Transitional Cell Carcinoma", "Cancer, Other", "Cancer, Anal", "Melanoma", "Cancer, Bile Duct", "Cancer, Bladder", "Cancer Cords Vocal", "Cancers Cell Neuroendocrine", "Cancer Differentiated Poorly", "Cancer, Anaplastic Thyroid" ], "interventions": [], "intervention_types": [], "sponsor": "SpeciCare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "99 Years", "sex": "ALL", "summary": "1 Month to 99 Years" }, "enrollment_count": 1000, "start_date": "2019-03-21", "completion_date": "2024-03-12", "has_results": false, "last_update_posted_date": "2020-12-04", "last_synced_at": "2026-05-22T04:51:54.391Z", "location_count": 1, "location_summary": "Gainesville, Georgia", "locations": [ { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896958" }, { "nct_id": "NCT00161187", "title": "Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 37, "start_date": "2001-05", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2015-11-06", "last_synced_at": "2026-05-22T04:51:54.391Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00161187" }, { "nct_id": "NCT00899496", "title": "Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "immunological diagnostic method", "type": "OTHER" }, { "name": "physiologic testing", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 54, "start_date": "2005-09", "completion_date": "2009-10-23", "has_results": false, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-05-22T04:51:54.391Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899496" }, { "nct_id": "NCT02955069", "title": "Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Well-differentiated Non-functional NET of Thoracic Origin", "Well-differentiated Non-functional NET of Gastrointestinal Origin", "Well-differentiated Non-functional NET of Pancreatic Origin", "Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "PDR001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2017-02-14", "completion_date": "2020-05-13", "has_results": true, "last_update_posted_date": "2021-04-12", "last_synced_at": "2026-05-22T04:51:54.391Z", "location_count": 7, "location_summary": "Duarte, California • Denver, Colorado • Tampa, Florida + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02955069" }, { "nct_id": "NCT00654238", "title": "Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Differentiated Thyroid Cancer", "Metastatic Poorly Differentiated Thyroid Cancer", "Metastatic Anaplastic Thyroid Cancer", "Metastatic Medullary Thyroid Cancer" ], "interventions": [ { "name": "sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2006-02", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2019-11-18", "last_synced_at": "2026-05-22T04:51:54.391Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00654238" }, { "nct_id": "NCT02250885", "title": "KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Neuroendocrine" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gabrail Cancer Center Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2014-08", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2019-09-17", "last_synced_at": "2026-05-22T04:51:54.391Z", "location_count": 1, "location_summary": "Canton, Ohio", "locations": [ { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02250885" }, { "nct_id": "NCT03630120", "title": "Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Cancer", "Thyroid Cancer, Medullary", "Differentiated Thyroid Cancer", "Papillary Thyroid Cancer", "Follicular Thyroid Cancer", "Poorly Differentiated Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Vandetanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2018-08-06", "completion_date": "2019-12-05", "has_results": true, "last_update_posted_date": "2021-07-14", "last_synced_at": "2026-05-22T04:51:54.391Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03630120" } ] }